EGFR and lung carcinoma: For instance, CL-387,785 inhibits colony formation by lung cancer cells expressing an EGFR missense or deletion mutant more effectively than gefitinib and erlotinib, suggesting that CL-387,785 may be a good therapeutic for lung cancer with exon 20 insertion mutations of EGFR (Greulich et al., 2005).